BRIEF—Ferring adds new indication for replacement growth hormone

Ferring Pharmaceuticals has been awarded US FDA approval for its Zomacton (somatropin) recombinant human growth hormone (GH) as a treatment for GH deficiency in adults.

The therapy is also indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, and has been marketed in the USA since 1988.

Adult growth hormone deficiency occurs in approximately 1-2 adults per 100,000.

Chief executive Paul Navarre said: "Ferring is committed to developing treatments that improve people's lives. We are pleased to add the adult indication to our existing endocrinology portfolio."